Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer
Clinical trial NCT07393425 · RECRUITING
Trial details
- NCT number
- NCT07393425
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-02-02
- Primary completion
- 2027-09-30
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.